Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790335 · ClinicalTrials.gov registry record · Phase 3
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
A Phase 3 study of Venous Thromboembolism and Deep Vein Thrombosis, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 692
- Enrollment target
- 20
- Study locations
NCT00790335 is a Phase 3 study of Venous Thromboembolism and Deep Vein Thrombosis that has completed, run by Washington University School of Medicine. The registered enrollment target is 692 participants, below the 6,281-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00790335, a Phase 3 study of Venous Thromboembolism and Deep Vein Thrombosis, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 692 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.
Conditions Studied
Interventions
- DRUG Recombinant tissue plasminogen activator (rt-PA)
Study Locations (20)
Florida
- Mease Countryside Hospital - Clearwater
- Baptist Cardiac & Vascular Institute - Miami
- Florida Hospital - Orlando
- Florida Hospital-Tampa Division-Pepin Heart Institute and Dr. Kiran C. Patel Research Institute - Tampa
Illinois
- University of Illinois at Chicago - Chicago
- Adventist Midwest Health - Hinsdale
- Southern Illinois University - Springfield
- Central DuPage Hospital - Winfield
California
- St. Joseph Hospital - Orange
- Stanford University Medical Center - Stanford
Connecticut
- Danbury Hospital - Danbury
- Eastern Connecticut Hematology and Oncology Associates - Norwich
Arizona
- Arrowhead Hospital/Phoenix Heart, PLLC - Glendale
Delaware
- Christiana Care Health Systems - Newark
District of Columbia
- Georgetown University Hospital - Washington D.C.
Indiana
- CorVasc - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 692 participants |
| Start Date | 2009-11 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790335
The ClinicalTrials.gov registry entry for NCT00790335 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 692 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,281-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (89% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Recombinant tissue plasminogen activator (rt-PA) is the first listed.
NCT00790335 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT00790335 about?
NCT00790335 is a clinical study titled "Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis". The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis...
What is the current status of trial NCT00790335?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 692 participants. The study started on 2009-11. Estimated completion is 2017-01.
What conditions does trial NCT00790335 study?
This clinical trial studies the following conditions: Venous Thromboembolism, Deep Vein Thrombosis, Venous Thrombosis, Post-Thrombotic Syndrome, Postphlebitic Syndrome.
What interventions are being tested in trial NCT00790335?
The interventions under investigation include: Recombinant tissue plasminogen activator (rt-PA) (DRUG).
Who is sponsoring clinical trial NCT00790335?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00790335 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
RECRUITING · Phase 3
-
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
COMPLETED · Phase 3
-
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
COMPLETED · Phase 3
-
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
COMPLETED · Phase 3
-
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.